SCHEMBL4639725

SCHEMBL4639725

Cc1cc(N)ccc1S(=O)(=O)N(C)C

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.63
ALDH1A1 P00352 6/20 0.45
CYP3A4 P08684 3/20 0.44
PDE2A O00408 1/20 0.44
PDE5A O76074 1/20 0.44
ALOX15 P16050 1/20 0.44
NFKB1 P19838 1/20 0.44
APEX1 P27695 1/20 0.44
PDE4A P27815 1/20 0.44
BLM P54132 1/20 0.44
PDE1B Q01064 1/20 0.44
PMP22 Q01453 1/20 0.44
PDE4B Q07343 1/20 0.44
PDE4D Q08499 1/20 0.44
PDE7A Q13946 1/20 0.44
PDE1C Q14123 1/20 0.44
PDE7B Q9NP56 1/20 0.44
PDE10A Q9Y233 1/20 0.41
MAPT P10636 2/20 0.41
MEN1 O00255 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7537342 0.85 ALDH1A1 (0.56) L3MBTL1ALDH1A1CYP3A4PDE2APDE5A
SCHEMBL29451752 0.85 ALDH1A1 (0.56) L3MBTL1ALDH1A1CYP3A4PDE2APDE5A
SCHEMBL11963454 0.80 LMNA (0.54) ALDH1A1CYP3A4PDE2APDE5AALOX15
SCHEMBL4363463 0.79 L3MBTL1 (0.73) L3MBTL1ALDH1A1CYP3A4ALOX15PDE10A
SCHEMBL31195184 0.79 ALDH1A1 (0.43) L3MBTL1ALDH1A1CYP3A4PDE2APDE5A
SCHEMBL4638477 0.79 ALDH1A1 (0.43) L3MBTL1ALDH1A1CYP3A4PDE2APDE5A
SCHEMBL4639664 0.79 ALDH1A1 (0.61) L3MBTL1ALDH1A1CYP3A4ALOX15MAPT
SCHEMBL13212960 0.79 CASP1 (0.44) L3MBTL1ALDH1A1CYP3A4PDE2APDE5A
SCHEMBL16364899 0.78 ALDH1A1 (0.55) L3MBTL1ALDH1A1CYP3A4PDE2APDE5A
SCHEMBL4639283 0.78 ALDH1A1 (0.42) L3MBTL1ALDH1A1CYP3A4PDE2APDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773768-A4 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2008-08-06 EP claimed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 EP claimed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 WO claimed
WO-2022032144-A1 SUBSTRATE ADAPTOR INHIBITORS OF PRMT5 AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2022-02-10 WO disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 L3MBTL1 4875/4885ALDH1A1 2251/4885CYP3A4 2500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.